U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Nelson HD, Helfand M. Screening for Postmenopausal Osteoporosis [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2002 Sep. (Systematic Evidence Reviews, No. 17.)

Cover
  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Screening for Postmenopausal Osteoporosis

Screening for Postmenopausal Osteoporosis [Internet].

Show details

References

1.
Melton L J 3rd, Kan S H, Frye M A, Wahner H W, O'Fallon W M, Riggs B L. Epidemiology of vertebral fractures in women. Am J Epidemiol. 1989;129:1000–11. [PubMed: 2784934]
2.
Barrett J A, Baron J A, Karagas M R, Beach M L. Fracture risk in the US Medicare population. J Clin Epidemiol. 1999;52:243–9. [PubMed: 10210242]
3.
Swedish Council on Technology Assessment in Healthcare. Bone density measurement-a systematic review. J Intern Med. 1997;241:1–60. [PubMed: 9104441]
4.
Hailey D, Sampietro-Colom L, Marshall D, et al. INAHTA project on the effectiveness of bone density measurement and associated treatments for prevention of fractures. Statement of findings. Edmonton, Alberta, Canada: Alberta Heritage Foundation for Medical Research, on behalf of the International Network of Agencies for Health Technology Assessment; 1996.
5.
Green CJ, Bassett K, Foerster V, Smith LL. Bone mineral density testing: does the evidence support its selective use in well women? Vancouver, British Columbia, Canada: British Columbia Office of Health Technology Assessment; 1997.
6.
National Osteoporosis Foundation. Osteoporosis: Review of the evidence for prevention, diagnosis, and treatment and cost-effectiveness analysis. Osteoporos Int. 1998;Suppl 4:S7-S88. [PubMed: 10197173]
7.
Homik J, Hailey D. Quantitative ultrasound for bone density measurement. Edmonton, Alberta, Canada: Alberta Heritage Foundation for Medical Research; 1998.
8.
Homik J, Hailey D. Selective testing with bone density measurement. Edmonton, Alberta, Canada: Alberta Heritage Foundation for Medical Research; 1999.
9.
Royal College of Physicians of London. Osteoporosis: Clinical guidelines for prevention and treatment. London; 1999.
10.
Blue Cross and Blue Shield Association. Ultrasonography of the heel for diagnostic osteoporosis and selecting patients for pharmacologic treatment. Chicago; 1999. [PubMed: 10848085]
11.
Siebzehner MI. Consensus statement on prevention and treatment of osteoporosis. Israel Center for Technology Assessment, Israel Medical Association. 1999. [PubMed: 10892399]
12.
US Preventive Services Task Force. Guide to clinical preventive services. Report of the US Preventive Services, 2nd Ed. Baltimore: Williams & Wilkins; 1996.
13.
Looker A C, Wahner L W, Dunn W L, Smith et al. Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int. 1998;8:468–89. [PubMed: 9850356]
14.
Melton L J 3rd. How many women have osteoporosis now? J Bone Miner Res. 1995;10:175–7. [PubMed: 7754796]
15.
Heaney R P. Bone mass, bone loss, and osteoporosis prophylaxis. Ann Intern Med. 1998;128:313–4. [PubMed: 9471936]
16.
White B, Fisher W, Lacerin C. Rate of mortality for elderly patients after fracture of hip in the 1980s. J Bone Joint Surg. 1987;69A:1335–40. [PubMed: 3440792]
17.
Cauley J, Thompson D, Ensrud K, Scott J, Black D. Risk of mortality following clinical fractures. Osteo Intern. 2000;11:556–61. [PubMed: 11069188]
18.
Melton L J 3rd. Epidemiology of spinal osteoporosis. Spine. 1997;22:2S–11S. [PubMed: 9431638]
19.
Gold D T. The clinical impact of vertebral fractures: quality of life in women with osteoporosis. Bone. 1996;18:S185–S189. [PubMed: 8777086]
20.
Chander J M, Martin A R, Girman C. et al. Reliability of an osteoporosis-targeted quality of life survey instrument for use in the community: OPT-QOL. Osteoporos Int. 1998;8:127–35. [PubMed: 9666935]
21.
Lyles K W, Gold D W, Shipp K M, Smith K K. Associatio of osteoporotic vertebral fractures with impaired functional status. Am J Med. 1993;94:595–601. [PubMed: 8506884]
22.
Consensus development conference: prophylaxis and treatment of osteoporosis. Am J Med. 1991;90:107–110. [PubMed: 1986575]
23.
Consensus development conference: diagnosis and treatment of osteoporosis. Am J Med 1993;94:646–50. [PubMed: 8506892]
24.
World Health Organization Technical Report Series. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. 1994;843:1–129. [PubMed: 7941614]
25.
Kanis J A. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Osteoporos Int. 1994;4:368–81. [PubMed: 7696835]
26.
Kanis JA, Gluer CC, Advisors. An update on the diagnosis and assessment of osteoporosis with densitometry. Osteoporos Int. 2000;11:192–202. [PubMed: 10824234]
27.
Harris R P, Helfand M, Woolf S H. et al. Current methods of the US Preventive Services Task Force. Am J Prev Med. 2001;20:21–35.
28.
Guyatt G. Systematic reviews of osteoporosis therapies: NIH Consensus Development Conference on Osteoporosis Prevention, Diagnosis and Therapy. Bethesda, MD: National Institutes of Health; 2000.
29.
Nelson H, Morris C, Kraemer D, et al. Osteoporosis in postmenopausal women: Diagnosis and monitoring. Rockville, MD: Agency for Healthcare Research and Quality; 2001.
30.
Falch J A, Sandvik L, Van Beresteijn E C. Development and evaluation of an index to predict early postmenopausal bone loss. Bone. 1992;13:337–41. [PubMed: 1389575]
31.
Verhaar H J, Koele J J, Neijzen T, Dessens J A, Duursma S A. Are arm span measurements useful in the prediction of osteoporosis in postmenopausal women? Osteoporos Int. 1998;8:174–6. [PubMed: 9666942]
32.
Elliot J R, Gilchrist N L, Wells J E, Ayling E, Turner J, Sainsbury R. Historical assessment of risk factors in screening for osteopenia in a normal Caucasian population. Aust N Z J Med. 1993;23:458–62. [PubMed: 8297274]
33.
Michaelsson K, Bergstrom R, Mallmin H, Holmberg L, Wolk A, Ljunghall S. Screening for osteopenia and osteoporosis: selection by body composition. Osteoporos Int. 1996;6:120–6. [PubMed: 8704349]
34.
Ballard P A, Purdie D W, Langton C M, Steel S A, Mussurakis S. Prevalence of osteoporosis and related risk factors in UK women in the seventh decade: osteoporosis case finding by clinical referral criteria or predictive model? Osteoporos Int. 1998;8:535–9. [PubMed: 10326057]
35.
Ribot C, Pouilles J M, Bonneu M, Tremollieres F. Assessment of the risk of post-menopausal osteoporosis using clinical factors. Clin Endocrinol. 1992;36:225–8. [PubMed: 1563075]
36.
Slemenda C W, Hui S L, Longcope C, Wellman H, Johnston C C Jr. Predictors of bone mass in perimenopausal women. A prospective study of clinical data using photon absorptiometry. Ann Intern Med. 1990;112:96–101. [PubMed: 2294827]
37.
Lydick E, Cook K, Turpin J, Melton M, Stine R, Byrnes C. Development and validation of a simple questionnaire to facilitate identification of women likely to have low bone density. Am J Manag Care. 1998;4:37–48. [PubMed: 10179905]
38.
Goemaere S, Zegels B, Toye K. et al. Limited clinical utility of a self-evaluating risk assessment scale for postmenopausal osteoporosis: lack of predictive value of lifestyle-related factors. Calcif Tissue Int. 1999;65:354–8. [PubMed: 10541759]
39.
Cadarette S M, Jaglal S B, Kreiger N, McIsaac W J, Darlington G A, Tu J V. Development and validation of the Osteoporosis Risk Assessment Instrument to facilitate selection of women for bone densitometry. Can Med Assoc J. 2000;162:1289–94. [PMC free article: PMC1232411] [PubMed: 10813010]
40.
Von Muhlen D, Visby Lunde A, Barrett-Connor E, Bettencourt R. Evaluation of the simple calculated osteoporosis risk estimation (SCORE) in older Caucasian women: the Rancho Bernardo study. Osteoporos Int. 1999;10:79–84. [PubMed: 10501784]
41.
Cadarette S, Jaglal S, Murray T, Mclsac W, Joesph L, Brown J. Evaluation of decision rules for referring women for bone densitometry by dual-energy x-ray absorptiometry. JAMA. 2001;286:57–63. [PubMed: 11434827]
42.
National Osteoporosis Foundation. Physician's guide to prevention and treatment of osteoporosis. Washington, D.C.: Excerpta Medica, Inc.; 1999.
43.
Weinstein L, Ullery B. Identification of at-risk women for osteoporosis screening. Am J Obstet Gynecol. 2000;183:547–549. [PubMed: 10992172]
44.
van Hemert A M, Vandenbroucke J P, Birkenhager J C, Valkenburg H A. Prediction of osteoporotic fractures in the general population by a fracture risk score. A 9-year follow-up among middle-aged women. Am J Epidemiol. 1990;132:123–35. [PubMed: 2192546]
45.
Ranstam J, Elffors L, Kanis J A. A mental-functional risk score for prediction of hip fracture. Age Ageing. 1996;25:439–42. [PubMed: 9003879]
46.
Burger H, de Laet C E, Weel A E, Hofman A, Pols H A. Added value of bone mineral density in hip fracture risk scores. Bone. 1999;25:369–74. [PubMed: 10495142]
47.
Tromp A M, Smit J H, Deeg D J, Bouter L M, Lips P. Predictors for falls and fractures in the Longitudinal Aging Study Amsterdam. J Bone Miner Res. 1998;13:1932–9. [PubMed: 9844112]
48.
Johnell O, Gullberg B, Kanis J A. et al. Risk factors for hip fracture in European women: the MEDOS Study. Mediterranean Osteoporosis Study. J Bone Miner Res. 1995;10:1802–15. [PubMed: 8592959]
49.
Wolinsky F D, Fitzgerald J F. The risk of hip fracture among noninstitutionalized older adults. J Gerontol. 1994;49:S165–75. [PubMed: 8014400]
50.
Kleerekoper M, Peterson E, Nelson D. et al. Identification of women at risk for developing postmenopausal osteoporosis with vertebral fractures: role of history and single photon absorptiometry. Bone Miner. 1989;7:171–86. [PubMed: 2804452]
51.
Cooper C, Shah S, Hand D J. et al. Screening for vertebral osteoporosis using individual risk factors. Osteoporos Int. 1991;2:48–53. [PubMed: 1790421]
52.
Blake GM, Gluer CC, Fogelman I. Bone densitometry: current status and future prospects. Br J Radiol. 1997;70 Spec No:S177–86. [PubMed: 9534732]
53.
Blake G M, Fogelman I. Applications of bone densitometry for osteoporosis. Endocrinol Metab Clin North Am. 1998;27:267–88. [PubMed: 9669138]
54.
Genant H K, Engelke K, Fuerst T. et al. Noninvasive assessment of bone mineral and structure: state of the art. J Bone Miner Res. 1996;11:707–30. [PubMed: 8725168]
55.
Jergas M, Genant H K. Spinal and femoral DXA for the assessment of spinal osteoporosis. Calcif Tissue Int. 1997;61:351–7. [PubMed: 9351874]
56.
Cameron J R, Sorenson J. Measurement of bone mineral in vivo: an improved method. Science. 1963;142:230–2. [PubMed: 14057368]
57.
Langton C M, Palmer S B, Porter R W. The measurement of broadband ultrasonic attenuation in cancellous bone. Eng Med. 1984;13:89–91. [PubMed: 6540216]
58.
Lochmuller E M, Eckstein F, Kaiser D. et al. Prediction of vertebral failure loads from spinal and femoral dual-energy X-ray absorptiometry, and calcaneal ultrasound: an in situ analysis with intact soft tissues. Bone. 1998;23:417–24. [PubMed: 9823447]
59.
Bouxsein M L, Radloff S E. Quantitative ultrasound of the calcaneus reflects the mechanical properties of calcaneal trabecular bone. J Bone Miner Res. 1997;12:839–46. [PubMed: 9144351]
60.
Bouxsein M L, Coan B S, Lee S C. Prediction of the strength of the elderly proximal femur by bone mineral density and quantitative ultrasound measurements of the heel and tibia. Bone. 1999;25:49–54. [PubMed: 10423021]
61.
Lochmuller E M, Zeller J B, Kaiser D. et al. Correlation of femoral and lumbar DXA and calcaneal ultrasound, measured in situ with intact soft tissues, with the in vitro failure loads of the proximal femur. Osteoporos Int. 1998;8:591–8. [PubMed: 10326066]
62.
Nicholson P H F, Muller R, Lowet G. et al. Do quantitative ultrasound measurements reflect structure independently of density in human vertebral cancellous bone? Bone. 1998;23:425–31. [PubMed: 9823448]
63.
Kotzki P O, Buyck D, Hans D. et al. Influence of fat on ultrasound measurements of the os calcis. Calcif Tissue Int. 1994;54:91–5. [PubMed: 8012877]
64.
Njeh C F, Boivin C M, Langton C M. The role of ultrasound in the assessment of osteoporosis: a review. Osteoporos Int. 1997;7:7–22. [PubMed: 9102067]
65.
Rico H, Gomez M, Aguado F, Villa L F, Hernandez E R, Cortes J. Impact of weight in obese subjects on bone speed of sound. Invest Radiol. 1999;34:596–9. [PubMed: 10485076]
66.
Gluer C C, Genant H K. Impact of marrow fat on accuracy of quantitative CT. J Comput Assist Tomogr. 1989;13:1023–35. [PubMed: 2584480]
67.
Howard G M, Nguyen T V, Pocock N A, Kelly P J, Eisman J A. Influence of handedness on calcaneal ultrasound: implications for assessment of osteoporosis and study design. Osteoporos Int. 1997;7:190–4. [PubMed: 9205629]
68.
Johansen A, Stone M D. The effect of ankle oedema on bone ultrasound assessment at the heel. Osteoporos Int. 1997;7:44–7. [PubMed: 9102062]
69.
Jones G, Nguyen T, Sambrook P N. et al. A longitudinal study of the effect of spinal degenerative disease on bone density in the elderly. J Rheumatol. 1995;22:932–6. [PubMed: 8587085]
70.
Agren M, Karellas A, Leahey D, Marks S, Baran D. Ultrasound attenuation of the calcaneus: a sensitive and specific discriminator of osteopenia in postmenopausal women. Calcif Tissue Int. 1991;48:240–4. [PubMed: 2059875]
71.
Alenfeld F E, Wuster C, Funck C. et al. Ultrasound measurements at the proximal phalanges in healthy women and patients with hip fractures. Osteoporos Int. 1998;8:393–8. [PubMed: 9850344]
72.
Cunningham J, Fordham J, Hewitt T, Speed C. Ultrasound velocity and attenuation at different skeletal sites compared with bone mineral density measured using dual energy X-ray absorptiometry. Br J Radiol. 1996;69:25–32. [PubMed: 8785618]
73.
Faulkner K G, McClung M R, Coleman L J, Kingston-Sandahl E. Quantitative ultrasound of the heel: correlation with densitometric measurements at different skeletal sites. Osteoporos Int. 1994;4:42–7. [PubMed: 8148571]
74.
Formica C A, Nieves J W, Cosman F, Garrett P, Lindsay R. Comparative assessment of bone mineral measurements using dual X-ray absorptiometry and peripheral quantitative computed tomography. Osteoporos Int. 1998;8:460–7. [PubMed: 9850355]
75.
Graafmans W C, Van Lingen A, Ooms M E, Bezemer P D, Lips P. Ultrasound measurements in the calcaneus: precision and its relation with bone mineral density of the heel, hip, and lumbar spine. Bone. 1996;19:97–100. [PubMed: 8853851]
76.
Grampp S, Jergas M, Lang P. et al. Quantitative CT assessment of the lumbar spine and radius in patients with osteoporosis. Am J Roentgenol. 1996;167:133–40. [PubMed: 8659357]
77.
Greenspan S L, Bouxsein M L, Melton M E. et al. Precision and discriminatory ability of calcaneal bone assessment technologies. J Bone Miner Res. 1997;12:1303–13. [PubMed: 9258762]
78.
Langton C M, Ballard P A, Bennett D K, Purdie D W. A comparison of the sensitivity and specificity of calcaneal ultrasound measurements with clinical criteria for bone densitometry (DEXA) referral. Clin Rheumatol. 1997;16:117–8. [PubMed: 9132320]
79.
Laval-Jeantet A M, Bergot C, Williams M, Davidson K, Laval-Jeantet M. Dual-energy X-ray absorptiometry of the calcaneus: comparison with vertebral dual-energy X-ray absorptiometry and quantitative computed tomography. Calcif Tissue Int. 1995;56:14–8. [PubMed: 7796340]
80.
Martin J, Reid D. Appendicular measurements in screening women for low axial bone mineral density. Br J Radiol. 1996;69:234–40. [PubMed: 8800867]
81.
Massie A, Reid D M, Porter R W. Screening for osteoporosis: comparison between dual energy X-ray absorptiometry and broadband ultrasound attenuation in 1000 perimenopausal women. Osteoporos Int. 1993;3:107–10. [PubMed: 8453190]
82.
Naganathan V, March L, Hunter D, Pocock N A, Markovey J, Sambrook P N. Quantitative heel ultrasound as a predictor for osteoporosis. Med J Aust. 1999;171:297–300. [PubMed: 10560444]
83.
Pocock N A, Noakes K A, Howard G M. et al. Screening for osteoporosis: what is the role of heel ultrasound? Med J Aust. 1996;164:367–70. [PubMed: 8606664]
84.
Rosenthall L, Tenenhouse A, Caminis J. A correlative study of ultrasound calcaneal and dual-energy X-ray absorptiometry bone measurements of the lumbar spine and femur in 1000 women. Eur J Nucl Med. 1995;22:402–6. [PubMed: 7641747]
85.
Roux C, Lemonnier E, Lolta S. et al. Broadband ultrasound attenuation of the calcaneus and bone density measurements. Rev Rhum Engl Ed. 1993;60:771–80.
86.
Salamone L, Krall E, Dawson-Hughes B. Comparison of broadband ultrasound attenuation to single X-ray absorptiometry measurements at the calcaneus in postmenopausal women. Calcif Tissue Int. 1994;54:87–90. [PubMed: 8012876]
87.
Schott A M, Weill-Engerer S, Hans D, Duboeuf F, Delmas P D, Meunier P J. Ultrasound discriminates patients with hip fracture equally well as dual energy X-ray absorptiometry and independently of bone mineral density. J Bone Miner Res. 1995;10:243–9. [PubMed: 7754803]
88.
Tromp A M, Smit J H, Deeg D J, Lips P. Quantitative ultrasound measurements of the tibia and calcaneus in comparison with DXA measurements at various skeletal sites. Osteoporos Int. 1999;9:230–5. [PubMed: 10450412]
89.
Turner C, Peacock M, Timmerman L, Neal J, Johnston C. Calcaneal ultrasonic measurements discriminate hip fracture independently of bone mass. Osteoporos Int. 1995;5:130–5. [PubMed: 7599449]
90.
Young H, Howey S, Purdie D W. Broadband ultrasound attenuation compared with dual-energy X-ray absorptiometry in screening for postmenopausal low bone density. Osteoporos Int. 1993;3:160–4. [PubMed: 8481593]
91.
Ahmed A I H, Blake G M, Rymer J M, Fogelman I. Screening for osteopenia and osteoporosis: do the accepted normal ranges lead to overdiagnosis? Osteoporos Int. 1997;7:432–38. [PubMed: 9425500]
92.
Petley G W, Cotton A M, Murrills A J. et al. Reference ranges of bone mineral density for women in southern England: the impact of local data on the diagnosis of osteoporosis. Br J Radiol. 1996;69:655–60. [PubMed: 8696703]
93.
Chen Z, Maricic M, Lund P, Tesser J, Gluck O. How the new Hologic hip normal reference values affect the densitometric diagnosis of osteoporosis. Osteoporos Int. 1998;8:423–27. [PubMed: 9850349]
94.
Simmons A, Barrington S, O'Doherty M, Coakley A. Dual energy X-ray absorptiometry normal reference range use within the UK and the effect of different normal ranges on the assessment of bone density. Br J Radiol. 1995;68:903–9. [PubMed: 7551789]
95.
Lunt M, Felsenberg D, Reeve J. et al. Bone density variation and its effects on risk of vertebral deformity in men and women studied in thirteen European centers: the EVOS Study. J Bone Miner Res. 1997;12:1883–94. [PubMed: 9383693]
96.
Laskey M, Crisp A, Cole T, Compston J. Comparison of the effect of different reference data on Lunar DPX and Hologic QDR-1000 dual-energy X-ray absorptiometers. Br J Radiol. 1992;65:1124–29. [PubMed: 1286422]
97.
Arlot M E, Sornay-Rendu E, Garnero P, Vey-Marty B, Delmas P D. Apparent pre- and postmenopausal bone loss evaluated by DXA at different skeletal sites in women: the OFELY cohort. J Bone Miner Res. 1997;12:683–90. [PubMed: 9101381]
98.
Faulkner K G, von Stetten E, Miller P. Discordance in patient classification using T-scores. J Clin Densitomet. 1999;2:343–50. [PubMed: 10548828]
99.
Grampp S, Henk C B, Fuerst T P. et al. Diagnostic agreement of quantitative sonography of the calcaneus with dual X-ray absorptiometry of the spine and femur. Am J Roentgenol. 1999;173:329–34. [PubMed: 10430129]
100.
Kroger H, Lunt M, Reeve J. et al. Bone density reduction in various measurement sites in men and women with osteoporotic fractures of spine and hip: the European quantitation of osteoporosis study. Calcif Tissue Int. 1999;64:191–9. [PubMed: 10024374]
101.
Varney L F, Parker R A, Vincelette A, Greenspan S L. Classification of osteoporosis and osteopenia in postmenopausal women is dependent on site-specific analysis. J Clin Densitomet. 1999;2:275–83. [PubMed: 10548823]
102.
Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312:1254–59. [PMC free article: PMC2351094] [PubMed: 8634613]
103.
Cummings S R, Black D M, Nevitt M C. et al. Bone density at various sites for prediction of hip fractures. Lancet. 1993;341:72–5. [PubMed: 8093403]
104.
Melton L J, Atkinson E, O'Fallon W, Wahner H, Riggs B. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res. 1993;8:1227–33. [PubMed: 8256660]
105.
Black D M, Cummings S R, Genant H K, Nevitt M C, Palermo L, Browner W. Axial and appendicular bone density predict fractures in older women. J Bone Miner Res. 1992;7:633–38. [PubMed: 1414481]
106.
Bauer D C, Gluer C C, Cauley J A. et al. Broadband ultrasound attenuation predicts fractures strongly and independently of densitometry in older women. A prospective study. Study of Osteoporotic Fractures Research Group. Arch Intern Med. 1997;157:629–34. [PubMed: 9080917]
107.
de Laet C E, Van Hout B A, Burger H, Weel A E, Hofman A, Pols H A. Hip fracture prediction in elderly men and women: validation in the Rotterdam study. J Bone Miner Res. 1998;13:1587–93. [PubMed: 9783547]
108.
Duboeuf F, Hans D, Schott A M. et al. Different morphometric and densitometric parameters predict cervical and trochanteric hip fracture: the EPIDOS Study. J Bone Miner Res. 1997;12:1895–902. [PubMed: 9383694]
109.
Garnero P, Dargent-Molina P, Hans D. et al. Do markers of bone resorption add to bone mineral density and ultrasonographic heel measurement for the prediction of hip fracture in elderly women? The EPIDOS prospective study. Osteoporos Int. 1998;8:563–9. [PubMed: 10326062]
110.
Hans D, Dargent-Molina P, Schott A M. et al. Ultrasonographic heel measurements to predict hip fracture in elderly women: the EPIDOS prospective study. Lancet. 1996;348:511–4. [PubMed: 8757153]
111.
Huang C, Ross P D, Yates A J. et al. Prediction of fracture risk by radiographic absorptiometry and quantitative ultrasound: a prospective study. Calcif Tissue Int. 1998;63:380–4. [PubMed: 9799821]
112.
Kroger H, Huopio J, Honkanen R. et al. Prediction of fracture risk using axial bone mineral density in a perimenopausal population: a prospective study. J Bone Miner Res. 1995;10:302–6. [PubMed: 7754811]
113.
Mele R, Masci G, Ventura V, de Aloysio D, Bicocchi M, Cadossi R. Three-year longitudinal study with quantitative ultrasound at the hand phalanx in a female population. Osteoporos Int. 1997;7:550–7. [PubMed: 9604051]
114.
Nevitt M C, Johnell O, Black D M, Ensrud K, Genant H K, Cummings S R. Bone mineral density predicts non-spine fractures in very elderly women. Study of Osteoporotic Fractures Research Group. Osteoporos Int. 1994;4:325–31. [PubMed: 7696827]
115.
Porter R W, Miller C G, Grainger D, Palmer S B. Prediction of hip fracture in elderly women: a prospective study. BMJ. 1990;301:638–41. [PMC free article: PMC1663899] [PubMed: 2224217]
116.
Schott A M, Cormier C, Hans D. et al. How hip and whole-body bone mineral density predict hip fracture in elderly women: the EPIDOS Prospective Study. Osteoporos Int. 1998;8:247–54. [PubMed: 9797909]
117.
Stewart A, Torgerson D J, Reid D M. Prediction of fractures in perimenopausal women: a comparison of dual energy x ray absortptiometry and broadband ultrasound attenuation. Ann Rheum Dis. 1996;55:140–2. [PMC free article: PMC1010110] [PubMed: 8712866]
118.
Vecht-Hart C M, Zwamborn A W, Peeters P H, Collette H J. Prediction of peripheral fracture risk by quantitative microdensitometry. Prev Med. 1997;26:86–91. [PubMed: 9010902]
119.
Rimes K A, Salkovskis P M, Shipman A J. Psychological and behavioural effects of bone density screening for osteoporosis. Psychol Health. 1999;14:585–608.
120.
Salamone L M, Pressman A R, Seeley D G, Cauley J A. Estrogen replacement therapy. A survey of older women's attitudes. Arch Intern Med. 1996;156:1293–7. [PubMed: 8651837]
121.
Silverman S L, Greenwald M, Klein R A. et al. Effect of bone density information on decisions about hormone replacement therapy: a randomized trial. Obstet Gynecol. 1997;89:321–5. [PubMed: 9052578]
122.
Rozenberg S, Kroll M, Vandromme J, Paesmans M, Ham H. Effect of bone density evaluation on hormone replacement therapy prescription. Maturitas. 1996;24:57–61. [PubMed: 8794435]
123.
Torgerson D J, Thomas R E, Campbell M K, Reid D M. Randomized trial of osteoporosis screening. Use of hormone replacement therapy and quality-of-life results. Arch Intern Med. 1997;157:2121–5. [PubMed: 9382669]
124.
Rubin S M, Cummings S R. Results of bone densitometry affect women's decisions about taking measures to prevent fractures. Ann Intern Med. 1992;116:990–95. [PubMed: 1586110]
125.
Stock J L, Waud C E, Coderre J A, Smith K K. Clinical reporting to primary care physicians leads to increased use and understanding of bone densitometry and affects the management of osteoporosis: a randomized trial. Ann Intern Med. 1998;128:996–9. [PubMed: 9625686]
126.
Torgerson D, Bell-Syer S. Hormone replacement therapy and prevention of nonvertebral fractures: A meta-analysis of randomized trials. JAMA. 2001;285:2891–2897. [PubMed: 11401611]
127.
Lufkin E, Wahner H, O'Fallon W. et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. An Intern Med. 1992;117:1–9. [PubMed: 1534476]
128.
Wimalawansa S. A four-year randomized controlled trial of hormone replacement and bisphosphate, alone or in combination, in women with postmenopausal osteoporosis. Am J Med. 1998;104:219–226. [PubMed: 9552083]
129.
Komulainen M H, Kroger H, Tuppurainen M T. et al. HRT and Vit D in prevention of non-vertebral fractures in postmenopausal women; a 5 year randomized trial. Maturitas. 1998;31:45–54. [PubMed: 10091204]
130.
Mosekilde L, Beck-Nielsen H, Sorensen O H. et al. Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women—results of the Danish Osteoporosis Prevention Study. Maturitas. 2000;36:181–193. [PubMed: 11063900]
131.
Cauley J, Black D. et al. Effects of hormone replacement therapy on clinical fractures and height loss: the heart and Estrogen/progestin Replacement Study (HERS). Am J Med. 2001;110:442–450. [PubMed: 11331055]
132.
Hulley S, Grady D, Bush T. et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Jama. 1998;280:605–13. [PubMed: 9718051]
133.
Cooper C, Melton L. Vertebral fractures: How large is the silent epidemic. BMJ. 1992;304:793–794. [PMC free article: PMC1881670] [PubMed: 1392705]
134.
Ettinger B, Black D, Mitlak B. et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA. 1999;282:637–645. [PubMed: 10517716]
135.
Lufkin E G, Whitaker M D, Nickelsen T. et al. Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. J Bone Miner Res. 1998;13:1747–54. [PubMed: 9797484]
136.
Fisher B, Costantino J P, Wickerham D L. et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371–88. [PubMed: 9747868]
137.
Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996:1535–41. [PubMed: 8950879]
138.
Adami S, Passeri M, Ortolani S, et al. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone. 1995:383–90. [PubMed: 8573412]
139.
Bone HG, Downs RW, Jr., Tucci JR, et al. Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers. J Clin Endocrinol Metab. 1997:265–74. [PubMed: 8989272]
140.
Chesnut CH, 3rd, McClung MR, Ensrud KE, et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J of Med. 1995:144–52. [PubMed: 7625419]
141.
Hosking D, Chilvers CE, Christiansen C, et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. NEJM. 1998:485–92. [PubMed: 9443925]
142.
Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. NEJM. 1995:1437–43. [PubMed: 7477143]
143.
McClung M, Clemmesen B, Daifotis A, et al. Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. An of Intern Med. 1998:253–61. [PubMed: 9471927]
144.
Greenspan S L, Parker R A, Ferguson L, Rosen H N, Maitland-Ramsey L, Karpf D B. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: A randomized clinical trial. J of Bone Miner Res. 1998;13:1431–8. [PubMed: 9738515]
145.
Pols HA, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Foxamax International Trial Study Group. Osteo Intern. 1999:461–8. [PubMed: 10550467]
146.
Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial . JAMA. 1998:2077–82. [PubMed: 9875874]
147.
Bonnick S, Rosen C, Mako B, DeLucca P, Byrnes C, Melton M. Alendronate vs calcium for treatment of osteoporosis in postmenopausal women. Bone. 1998;23(5S):S476.
148.
Ensrud KE, Black DM, Palermo L, et al. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. Arch Intern Med. 1997:2617–24. [PubMed: 9531231]
149.
Cummings S R, Black D M, Thompson D E. Effect of alendronate reduces on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280:2077–82. [PubMed: 9875874]
150.
McClung M, Geusens P, Miller P. et al. Effect of risedronate on the risk of hip fracture in elderly women. NEJM. 2001;344:333–40. [PubMed: 11172164]
151.
Johansen H K, Gotzsche P C. Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. JAMA. 1999;282:1752–9. [PubMed: 10568648]
152.
Djulbegovic B, Lacevic M, Cantor A. et al. The uncertainty principle and industry-sponsored research. Lancet. 2000;356:635–38. [PubMed: 10968436]
153.
Miller J, Chan B, Nelson H. Postmenopausal estrogen replacement and risk of venous thromboembolism: A systematic review and meta-analysis. Rockville, MD: Agency for Healthcare Research and Quality; 2001.
154.
Grodstein F, Colditz G, Stampfer M. Postmenopausal hormone use and cholecystectomy in a large prospective study. Obstet Gynecol. 1994;85:5–11. [PubMed: 8272307]
155.
Grady D, Gebretsadik T, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: A meta-analysis. Obstet Gynecol. 1995;85:304–313. [PubMed: 7824251]
156.
Rodriguez I, Kilborn M J, Liu X K, Pezzullo J C, Woosley R L. Drug-induced QT prolongation in women during the menstrual cycle. JAMA. 2001;285:1322–6. [PubMed: 11255387]
157.
Collaborative Group on Hormonal Factors in Breast Cancer: Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047–59. [PubMed: 10213546]
158.
Humphrey L, Takana L. Postmenapausal hormone replacement therapy and cardiovascular disease: Systematic evidence review. Rockville, MD: Agency for Healthcare Research and Quality; 2001. [PubMed: 20722105]
159.
Davies G, Huster W, Lu Y, Plouffe L J, Lakshmanan M. Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet and Gynecol. 1999;93:558–65. [PubMed: 10214833]
160.
Ettinger B, Pressman A, Schein J. Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis. Am J Manag Care. 1998;4:1377–82. [PubMed: 10338731]
161.
Melton L J, Chrischilles E A, Cooper C, Lane A W, Riggs B L. Perspective. How many women have osteoporosis? J Bone Miner Res. 1992;7:1005–10. [PubMed: 1414493]
162.
Reginster J, Minne H, Sorensen O. et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis: Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteo Intern. 2000;11:83–91. [PubMed: 10663363]
163.
Meyer H E, Tverdal A, Falch J A. Risk factors for hip fracture in middle-aged Norwegian women and men. Am J Epidemiol. 1993;137:1203–11. [PubMed: 8322761]
164.
Fujiwara S, Kasagi F, Yamada M, Kodama K. Risk factors for hip fracture in a Japanese cohort. J Bone Miner Res. 1997;12:998–1004. [PubMed: 9199997]
165.
Kreiger N, Gross A, Hunter G. Dietary factors and fracture in postmenopausal women: a case-control study. Int J Epidemiol. 1992;21:953–8. [PubMed: 1468859]
166.
Tuppurainen M, Kroger H, Honkanen R. et al. Risks of perimenopausal fractures--a prospective population-based study. Acta Obstet Gynecol Scand. 1995;74:624–8. [PubMed: 7660769]
167.
Mallmin H, Ljunghall S, Persson I, Bergstrom R. Risk factors for fractures of the distal forearm: a population-based case-control study. Osteoporos Int. 1994;4:298–304. [PubMed: 7696821]
168.
Honkanen R, Tuppurainen M, Kroger H, Alhava E, Saarikoski S. Relationships between risk factors and fractures differ by type of fracture: a population-based study of 12,192 perimenopausal women. Osteoporos Int. 1998;8:25–31. [PubMed: 9692074]
169.
Torgerson D J, Campbell M K, Thomas R E, Reid D M. Prediction of perimenopausal fractures by bone mineral density and other risk factors. J Bone Miner Res. 1996;11:293–7. [PubMed: 8822354]
170.
Weinstein L, Ullery B, Bourguignon C. A simple system to determine who needs osteoporosis screening. Obstet Gyn. 1999;93:757–60. [PubMed: 10912981]
171.
Tobias J H, Cook D G, Chambers T J, Dalzell N. A comparison of bone mineral density between Caucasian, Asian and Afro-Caribbean women. Clin Sci. 1994;87:587–91. [PubMed: 7874848]
172.
Farmer M E, White L R, Brody J A, Bailey K R. Race and sex differences in hip fracture incidence. Am J Public Health. 1984;74:1374–80. [PMC free article: PMC1652702] [PubMed: 6507690]
173.
Bauer R L. Ethnic differences in hip fracture: a reduced incidence in Mexican Americans. Am J Epidemiol. 1988;127:145–9. [PubMed: 3337072]
174.
Grisso J A, Kelsey J L, Strom B L. et al. Risk factors for hip fracture in black women. The Northeast Hip Fracture Study Group. N Engl J Med. 1994;330:1555–9. [PubMed: 8177244]
175.
Suzuki T, Yoshida H, Hashimoto T. et al. Case-control study of risk factors for hip fractures in the Japanese elderly by a Mediterranean Osteoporosis Study (MEDOS) questionnaire. Bone. 1997;21:461–7. [PubMed: 9356741]
176.
Agency for Health Care Policy and Research, U.S. Department of Health and Human Services. Health Technology Assessment. Number 6: Bone Densitometry: Patients with Asymptomatic Hyperparathyroidism. 1995;AHRQ Pub.:96-0004.
Copyright Notice
Bookshelf ID: NBK42758
Contents

Views

  • PubReader
  • Print View
  • Cite this Page

Other titles in these collections

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...